Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.58 |
| ▸ | CA2 | P00918 | 2/20 | 0.58 |
| ▸ | CA7 | P43166 | 2/20 | 0.58 |
| ▸ | CA9 | Q16790 | 2/20 | 0.58 |
| ▸ | CA12 | O43570 | 1/20 | 0.58 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.58 |
| ▸ | ACHE | P22303 | 1/20 | 0.48 |
| ▸ | APP | P05067 | 3/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | IDO1 | P14902 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4707838 | 0.86 | NQO1 (0.47) | CA1CA2CA7CA9CA12 | |
| SCHEMBL72510 | 0.80 | CA12 (0.52) | CA1CA2CA7CA9CA12 | |
| SCHEMBL3166151 | 0.79 | ALDH1A1 (0.58) | CA1CA2CA7CA9CA12 | |
| SCHEMBL9664138 | 0.79 | NQO1 (0.74) | CA1CA2CA7CA9CA12 | |
| SCHEMBL426483 | 0.79 | DRD2 (0.48) | ACHETDP1MAOBMAPTL3MBTL1 | |
| SCHEMBL1047649 | 0.78 | DRD2 (0.52) | CA1CA2CA7CA9CA12 | |
| SCHEMBL1343630 | 0.78 | CA12 (0.65) | CA1CA2CA7CA9CA12 | |
| SCHEMBL10637391 | 0.78 | CA1 (0.65) | CA1CA2CA7CA9CA12 | |
| SCHEMBL535412 | 0.77 | MAOB (0.58) | CA1CA2CA7CA9ACHE | |
| SCHEMBL1044851 | 0.77 | MAPT (0.53) | CA1CA2CA7CA9CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 273 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3172259-B1 | NOVEL POLYMERS CONTAINING SULPHONAMIDE SODIUM OR LITHIUM SALTS, PRODUCTION METHODS THEREOF AND USES OF SAME AS ELECTROLYTES FOR BATTERIES | CDP INNOVATION (FR) | 2021-05-19 | — | — | EP | claimed |
| CN-106754853-B | Irreversible affinity labeling reagent for labeling GST and application | 重庆医科大学 | 2020-02-04 | — | — | CN | claimed |
| CN-107004455-B | New polymers, preparation method containing sulfonamide sodium or lithium salts and its purposes as cell electrolyte | CDP创新公司 | 2019-07-16 | — | — | CN | claimed |
| US-10109883-B2 | Polymers containing sulfonamide sodium or lithium salts, methods for production thereof and uses of same as electrolytes for batteries | CPD INNOVATION (FR) | 2018-10-23 | — | — | US | claimed |
| CN-107004455-A | New polymers, its preparation method containing sulfonamide sodium or lithium salts and its purposes as cell electrolyte | CDP创新公司 | 2017-08-01 | — | — | CN | claimed |
| US-20170170516-A1 | NOVEL POLYMERS CONTAINING SULFONAMIDE SODIUM OR LITHIUM SALTS, METHODS FOR PRODUCTION THEREOF AND USES OF SAME AS ELECTROLYTES FOR BATTERIES | CDP INNOVATION (FR) | 2017-06-15 | — | — | US | claimed |
| EP-2200440-A1 | ANTIBACTERIAL AMIDE AND SULFONAMIDE SUBSTITUTED HETEROCYCLIC UREA COMPOUNDS | Crestone, Inc. (US) | 2010-06-30 | — | — | EP | claimed |
| US-7671089-B2 | Levodopa prodrugs, and compositions and uses thereof | XENOPORT, INC. (US) | 2010-03-02 | — | — | US | claimed |
| US-20100004332-A1 | Levodopa Prodrugs, and Compositions and Uses Thereof | XENOPORT, INC. (US) | 2010-01-07 | — | — | US | claimed |
| WO-2009015208-A1 | ANTIBACTERIAL AMIDE AND SULFONAMIDE SUBSTITUTED HETEROCYCLIC UREA COMPOUNDS | REPLIDYNE, INC. (US) | 2009-01-29 | — | — | WO | claimed |
| EP-0766665-A2 | METALLOPROTEINASE INHIBITORS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1997-04-09 | — | — | EP | claimed |
| WO-1995035276-A1 | METALLOPROTEINASE INHIBITORS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1995-12-28 | — | — | WO | claimed |
| WO-1995035275-A1 | METALLOPROTEINASE INHIBITORS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1995-12-28 | — | — | WO | claimed |
| EP-0159584-B1 | N-(AZOLYLCARBAMOYL)-HYDROXYL AMINES AND FUNGICIDES CONTAINING THEM | BASF Aktiengesellschaft (DE) | 1989-01-18 | — | — | EP | claimed |
| US-4689411-A | ANTIBIOTICS | OTSUKA KAGAKU YAKUHIN KABUSHIKI KAISHA (JP) | 1987-08-25 | — | — | US | claimed |
| US-4678798-A | PLANTS, SEEDS | BASF AKTIENGESELLSCHAFT (DE) | 1987-07-07 | — | — | US | claimed |
| EP-0159584-A2 | N-(azolylcarbamoyl)-hydroxyl amines and fungicides containing them | BASF Aktiengesellschaft (DE) | 1985-10-30 | — | — | EP | claimed |
| US-4252716-A | BLUE SHADES | BAYER AKTIENGESELLSCHAFT (DE) | 1981-02-24 | — | — | US | claimed |
| US-4000141-A | SUBSTITUTED TETRAHYDRO QUINOLINE CATIONIC DYESTUFFS | BAYER AKTIENGESELLSCHAFT (DT) | 1976-12-28 | — | — | US | claimed |
| US-3991042-A | Basic azo dyestuffs containing a benzthiazole and a tetrahydroquinoline nucleus | BAYER AKTIENGESELLSCHAFT (DT) | 1976-11-09 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004332-A1 | Levodopa Prodrugs, and Compositions and Uses Thereof | COMT, DDT, DDC | CA1 3469/4885CA2 4601/4885CA7 3171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.